A retrospective review of calcium hydroxylapatite for correction of volume loss in the infraorbital region.
BACKGROUND
The correction of infraorbital volume loss with dermal fillers results in a natural, youthful, rested appearance. Defects in this facial region should be treated for optimal patient satisfaction.


OBJECTIVE
This retrospective review describes large-scale use of injection of calcium hydroxylapatite (CaHA) and a technique for injection into the infraorbital region.


METHODS
Using a 30-gauge, 0.5 needle, CaHA was injected into the infraorbital region of 301 patients. Neat CaHA was initially twice diluted with lidocaine 2% solution in 85 patients. Subsequently, 216 patients were treated with single-dilution CaHA and 0.15 mL of 2% lidocaine.


RESULTS
Injection of CaHa through a 30-gauge, 0.5 needle resulted in minimal bruising, discomfort, or pain. Infraorbital volume restoration was achieved efficiently and effectively, with natural results. Patients were satisfied with the longevity of correction. Adverse events were few and confined to ecchymosis (10%), edema (2%), and erythema (1%). Three of six patients reported edema lasting beyond 7 days. No overcorrection was observed.


CONCLUSIONS
Using a 30-gauge, 0.5 needle, diluted CaHA can be safely injected into the infraorbital region with minimal adverse events and high patient satisfaction.
Hevia
Oscar
O
Private Practice, Miami, Florida, USA. liponet@aol.com
D000368:Aged; D000369:Aged, 80 and over; D001672:Biocompatible Materials / Q000008:administration & dosage*; D017886:Durapatite / Q000008:administration & dosage*; D005123:Eye; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D012189:Retrospective Studies; D015595:Skin Aging
D001672:Biocompatible Materials; D017886:Durapatite